Caseware UK (AP4) 2025.0.111 2025.0.111 2026-04-302026-04-30The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.2025-05-01falseNo description of principal activity11truetruefalse 11302109 2025-05-01 2026-04-30 11302109 2024-05-01 2025-04-30 11302109 2026-04-30 11302109 2025-04-30 11302109 2024-05-01 11302109 c:Director1 2025-05-01 2026-04-30 11302109 d:OfficeEquipment 2025-05-01 2026-04-30 11302109 d:OfficeEquipment 2026-04-30 11302109 d:OfficeEquipment 2025-04-30 11302109 d:OfficeEquipment d:OwnedOrFreeholdAssets 2025-05-01 2026-04-30 11302109 d:ComputerEquipment 2025-05-01 2026-04-30 11302109 d:ComputerEquipment 2026-04-30 11302109 d:ComputerEquipment 2025-04-30 11302109 d:ComputerEquipment d:OwnedOrFreeholdAssets 2025-05-01 2026-04-30 11302109 d:OwnedOrFreeholdAssets 2025-05-01 2026-04-30 11302109 d:CurrentFinancialInstruments 2026-04-30 11302109 d:CurrentFinancialInstruments 2025-04-30 11302109 d:CurrentFinancialInstruments d:WithinOneYear 2026-04-30 11302109 d:CurrentFinancialInstruments d:WithinOneYear 2025-04-30 11302109 d:ShareCapital 2026-04-30 11302109 d:ShareCapital 2025-04-30 11302109 d:RetainedEarningsAccumulatedLosses 2026-04-30 11302109 d:RetainedEarningsAccumulatedLosses 2025-04-30 11302109 c:OrdinaryShareClass1 2025-05-01 2026-04-30 11302109 c:OrdinaryShareClass1 2026-04-30 11302109 c:OrdinaryShareClass1 2025-04-30 11302109 c:OrdinaryShareClass2 2025-05-01 2026-04-30 11302109 c:OrdinaryShareClass2 2026-04-30 11302109 c:OrdinaryShareClass2 2025-04-30 11302109 c:OrdinaryShareClass3 2025-05-01 2026-04-30 11302109 c:OrdinaryShareClass3 2026-04-30 11302109 c:OrdinaryShareClass3 2025-04-30 11302109 c:OrdinaryShareClass4 2025-05-01 2026-04-30 11302109 c:OrdinaryShareClass4 2026-04-30 11302109 c:OrdinaryShareClass4 2025-04-30 11302109 c:FRS102 2025-05-01 2026-04-30 11302109 c:AuditExempt-NoAccountantsReport 2025-05-01 2026-04-30 11302109 c:FullAccounts 2025-05-01 2026-04-30 11302109 c:PrivateLimitedCompanyLtd 2025-05-01 2026-04-30 11302109 d:AcceleratedTaxDepreciationDeferredTax 2026-04-30 11302109 d:AcceleratedTaxDepreciationDeferredTax 2025-04-30 11302109 e:PoundSterling 2025-05-01 2026-04-30 xbrli:shares iso4217:GBP xbrli:pure

Registered number: 11302109










SCHEUERMANN-FREESTONE CARDIOLOGY LTD








UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 30 APRIL 2026

 
SCHEUERMANN-FREESTONE CARDIOLOGY LTD
REGISTERED NUMBER: 11302109

STATEMENT OF FINANCIAL POSITION
AS AT 30 APRIL 2026

2026
2025
Note
£
£

Fixed assets
  

Tangible assets
 4 
2,533
2,994

  
2,533
2,994

Current assets
  

Debtors: amounts falling due within one year
 5 
7,422
10,264

Cash at bank and in hand
  
259,763
267,172

  
267,185
277,436

Creditors: amounts falling due within one year
 6 
(18,456)
(19,425)

Net current assets
  
 
 
248,729
 
 
258,011

Total assets less current liabilities
  
251,262
261,005

Provisions for liabilities
  

Deferred tax
 7 
(633)
(748)

  
 
 
(633)
 
 
(748)

Net assets
  
250,629
260,257


Capital and reserves
  

Called up share capital 
 8 
100
100

Profit and loss account
  
250,529
260,157

  
250,629
260,257


Page 1

 
SCHEUERMANN-FREESTONE CARDIOLOGY LTD
REGISTERED NUMBER: 11302109

STATEMENT OF FINANCIAL POSITION (CONTINUED)
AS AT 30 APRIL 2026

The director considers that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The director acknowledges her responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of comprehensive income in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 




M Scheuermann-Freestone
Director
Date: 22 October 2026

The notes on pages 3 to 7 form part of these financial statements.

Page 2

 
SCHEUERMANN-FREESTONE CARDIOLOGY LTD
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2026

1.


General information

Scheuermann-Freestone Cardiology Ltd is a private company limited by share capital and incorporated in England and Wales. The registered office is Lavendel Haus, 3 Manor Close, Chilton, Didcot, Oxfordshire, OX11 0SS.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The following principal accounting policies have been applied:

 
2.2

Revenue

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable for services during the year, excluding discounts, rebates, value added tax and other sales taxes.

 
2.3

Current and deferred taxation

The tax expense for the year comprises current and deferred tax. Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the Company operates and generates income.

Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the reporting date, except that:
∙The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and
∙Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met.

Deferred tax balances are not recognised in respect of permanent differences except in respect of business combinations, when deferred tax is recognised on the differences between the fair values of assets acquired and the future tax deductions available for them and the differences between the fair values of liabilities acquired and the amount that will be assessed for tax. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the reporting date.


 
2.4

Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Page 3

 
SCHEUERMANN-FREESTONE CARDIOLOGY LTD
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2026

2.Accounting policies (continued)


2.4
Tangible fixed assets (continued)

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives. 

Depreciation is provided on the following basis:

Office equipment
-
25%
reducing balance
Computer equipment
-
25%
straight-line method

 
2.5

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
2.6

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.7

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

 
2.8

Financial instruments

The Company has elected to apply the provisions of Section 11 “Basic Financial Instruments” of FRS 102 to all of its financial instruments.

Basic financial assets

Basic financial assets, which include trade and other debtors, cash and bank balances, are initially measured at their transaction price (adjusted for transaction costs except in the initial measurement of financial assets that are subsequently measured at fair value through profit and loss) and are subsequently carried at their amortised cost using the effective interest method, less any provision for impairment, unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest.

Discounting is omitted where the effect of discounting is immaterial. The Company's cash and cash equivalents, trade and most other debtors due with the operating cycle fall into this category of financial instruments.

 
2.9

Dividends

Equity dividends are recognised when they become legally payable. Interim equity dividends are recognised when paid. Final equity dividends are recognised when approved by the shareholders at an annual general meeting.

Page 4

 
SCHEUERMANN-FREESTONE CARDIOLOGY LTD
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2026

3.


Employees




The average monthly number of employees, including directors, during the year was 1 (2025 - 1).


4.


Tangible fixed assets


Office equipment
Computer equipment
Total

£
£
£



Cost or valuation


At 1 May 2025
3,189
6,692
9,881


Additions
-
699
699



At 30 April 2026

3,189
7,391
10,580



Depreciation


At 1 May 2025
2,015
4,872
6,887


Charge for the year on owned assets
294
866
1,160



At 30 April 2026

2,309
5,738
8,047



Net book value



At 30 April 2026
880
1,653
2,533



At 30 April 2025
1,174
1,820
2,994


5.


Debtors

2026
2025
£
£


Trade debtors
6,069
7,891

Prepayments and accrued income
1,353
2,373

7,422
10,264


Page 5

 
SCHEUERMANN-FREESTONE CARDIOLOGY LTD
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2026

6.


Creditors: amounts falling due within one year

2026
2025
£
£

Corporation tax
4,913
6,776

Other creditors
9,463
8,749

Accruals and deferred income
4,080
3,900

18,456
19,425



7.


Deferred taxation




2026
2025


£

£






At beginning of year
(748)
(849)


Charged to profit or loss
115
101



At end of year
(633)
(748)

The provision for deferred taxation is made up as follows:

2026
2025
£
£


Accelerated capital allowances
(633)
(748)

(633)
(748)


8.


Share capital

2026
2025
£
£
Allotted, called up and fully paid



85 (2025 - 85) Ordinary shares of £1.00 each
85
85
5 (2025 - 5) A Ordinary shares of £1.00 each
5
5
5 (2025 - 5) B Ordinary shares of £1.00 each
5
5
5 (2025 - 5) C Ordinary shares of £1.00 each
5
5

100

100

All shares rank pari passu with each other, however the directors have the authority to pay differing rates of dividends on each class of share.


Page 6

 
SCHEUERMANN-FREESTONE CARDIOLOGY LTD
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2026

9.


Related party transactions

At the balance sheet date the Company owed its director £9,463 (2025: £8,749). The loan is interest free and repayable on demand.


Page 7